Member Biography

• Brain Tumor Imaging: Identification of a brain tumor imaging biomarker which reliably precedes high grade glioma progression by 3.5-4 months. This work has extensive preliminary data and is in the end-phases of being validated using artificial intelligence - deep machine learning as well as through an established collaboration with the EORTC using a prospectively collected centrally reviewed cohort of newly diagnosed GBM patients on the CORE and CENTRIC clinical trials. • Population Science: Understanding rural populations with glioblastoma (GBM) - Retrospective review of over 800 patients diagnosed with glioblastoma between 2006 and 2019 to compare to national averages in survival, location, parity, occupation, marital status, gender/sex, race, education, Insurance, co-morbid histories, body mass index, and tumor location to compare to national or otherwise matched historical data. Our goal is to identify the features that might better characterize the rural GBM and offer insight into health disparities and vulnerabilities that drive GBM outcomes in rural populations. The goal of this work would be to allow for earlier estimation of tumor risk factors that may better apply to patients and rural populations. • Leptomeningeal carcinomatosis (LMC) is a rare complication of systemic cancer resulting in metastasis to the cerebrospinal fluid (CSF). This is a rapidly fatal condition that remains poorly understood. Assessment of treated and untreated leptomeningeal disease patients and characterized their imaging, brain fluid, cancer control, and other demographic features that might help us best characterized the largest cohort of leptomeningeal disease patients studied (to our knowledge) in retrospective fashion to identify common brain imaging changes, CSF characteristics, and patient clinical and demographic data that correlate with systemic disease progression. The goal of this work would be for earlier determination of systemic progression for sooner intervention or to limit clinical decline and extend patient quality survival. • Meningioma – With our collaborators, we have collected data for over 6000 patients with the diagnosis of meningioma between 2000 and 2024. Patient were sorted into presumed (diagnosis based on imaging and clinical history) versus tissue pathology confirmed diagnosis (anticipated 30%). Tumors are sorted by grade, aggressiveness (location, tumor markers, and recurrence), identifiable patient demographic (age, sex, race…), patient smoking history, patient hormone replacement exposure, patient parity, and BMI. We believe continued studies in this area would be a benefit treatment and clinical trial design in what is still the most common primary brain tumor. • CNS Malignancies – Neuroimmune Function, and Genomic/Proteomic Implications: This work will require extensive collaborative partners across multiple clinical and research disciplines including: neuro-oncology, surgery, medical oncology, pathology, precision genomics, radiation oncology, radiology, psychology, and physical medicine and rehabilitation. The goal of this work would be to use various scientific core, basic science, and translational research laboratories along with EMR data assisted by artificial intelligence to develop a substantial patient registry for real-time and retrospective assessment of clinical, histopathologic, molecular, and imaging features that offer insight into the immunologic and microenvironmental mechanisms for CNS metastasis and CNS tumor oncogenicity. This work will aid in the development of a body of research (clinical trials and basic/translational science) aimed to earlier identify patients at risk for CNS tumor progression, or offer opportunities for drug development to target vulnerable patients based on identified immunological, molecular genetics, or imaging characteristic. Complete List of Published Work in MyBibliography: https://www.ncbi.nlm.nih.gov/myncbi/na%20tosha.gatson.1/bibliography/public/

Post-doctoral Fellowship - The Ohio State University Wexner Medical Center, Columbus, OH 2011-2012

Residency - The Ohio State University Wexner Medical Center, Columbus, OH 2009-2014

Internship - The Ohio State University College of Medicine, Columbus, OH 2009-2010

Ph.D. - The Ohio State University College of Medicine, Columbus, OH 2002-2006

M.D. - The Ohio State University College of Medicine, Columbus, OH 2000-2009